Patents by Inventor Ronald Sake Oosting

Ronald Sake Oosting has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240269243
    Abstract: The treatment of neurodegenerative diseases, i.e. a group of chronic, progressive disorders characterized by the gradual loss of neurons or neuronal function in discrete areas of the central nervous system (CNS). Specifically, alkaline phosphatase (AP) for use in the treatment or prophylaxis of a mammal suffering from or at risk of a neurodegenerative disorder caused by a reduction of Peroxisome proliferator-activated receptor gamma coactivator 1 (PGC1) activity.
    Type: Application
    Filed: June 8, 2022
    Publication date: August 15, 2024
    Applicant: AMRIF B.V.
    Inventors: Ronald Sake Oosting, Hiskias Gerrit Keizer, Rudi Brands, Willem Seinen, Herman Feil
  • Patent number: 11103562
    Abstract: Present invention relates to a composition for use in the treatment of arthritides. Alkaline phosphatase (AP), an ectophosphatase with an anti-inflammatory and barrier protecting mechanism of action shows potent anti-rheumatoid arthritis (anti-RA) efficacy in a rat model for arthritis. In this model RA was induced by subcutaneous immunization with a mixture of methylated bovine serum albumin (mBSA), CFA (complete Freund's adjuvant antigen) and CBP (custom Bordetella pertussis antigen) and intra-articular injections of mBSA. Results were comparable with those obtained for MTX, the drug reference compound for the treatment of RA. Both knee swelling over time and the number of invading macrophages were found to be reduced with AP treatment, either applied in prophylactic treatment or therapeutic treatment, and comparable to the MTX effects. AP was found effective both as prophylactic, and as therapeutic intervention.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: August 31, 2021
    Assignee: AMRIF BV
    Inventors: Rudi Brands, Willem Seinen, Carolina Frederika Maria Molthoff, Gerrit Jansen, Ronald Sake Oosting
  • Publication number: 20200121765
    Abstract: Present invention relates to a composition for use in the treatment of arthritides. Alkaline phosphatase (AP), an ectophosphatase with an anti-inflammatory and barrier protecting mechanism of action shows potent anti-rheumatoid arthritis (anti-RA) efficacy in a rat model for arthritis. In this model RA was induced by subcutaneous immunization with a mixture of methylated bovine serum albumin (mBSA), CFA (complete Freund's adjuvant antigen) and CBP (custom Bordetella pertussis antigen) and intra-articular injections of mBSA. Results were comparable with those obtained for MTX, the drug reference compound for the treatment of RA. Both knee swelling over time and the number of invading macrophages were found to be reduced with AP treatment, either applied in prophylactic treatment or therapeutic treatment, and comparable to the MTX effects. AP was found effective both as prophylactic, and as therapeutic intervention.
    Type: Application
    Filed: December 12, 2017
    Publication date: April 23, 2020
    Inventors: Rudi Brands, Willem Seinen, Carolina Frederika Maria Molthoff, Gerrit Jansen, Ronald Sake Oosting